Safety and efficacy of minimally invasive splenectomy with endotherapy for non-cirrhotic portal fibrosis: a retrospective cohort study.

Non-cirrhotic portal fibrosis (NCPF), a leading cause of non-cirrhotic portal hypertension (NCPH), commonly presents with splenomegaly, esophageal varices, and preserved liver function. While minimally invasive splenectomy (MIS) offers advantages over open splenectomy, concerns persist due to the risks associated with portal hypertension. This study evaluates the feasibility, safety, and long-term outcomes of MIS in non-bleeder NCPF patients, highlighting perioperative challenges and techniques. Thirteen consecutive non-bleeder NCPF patients undergoing MIS between November 2017 and December 2023 were analyzed. Procedures included eight laparoscopic and four robotic splenectomies, with one conversion to open surgery. Additionally, two patients underwent laparoscopic and one robotic gastric devascularization. Perioperative parameters such as operative time, blood loss, hospital stay, and complications were recorded. The median operative time was 240 minutes, and median blood loss was 150 mL. One patient required transfusion, and one developed splanchnic venous thrombosis, managed conservatively. Median hospital stay was three days, with no 90-day mortality. Follow-up assessments included clinical evaluation, blood tests, Doppler ultrasound of the splenoportal axis, and upper gastrointestinal endoscopy. At a median follow-up of 16 months (interquartile range 12-43), significant improvements were observed in hemoglobin, leukocyte, and platelet counts (p < 0.01). Esophageal variceal grades decreased from 2 to 1, while portal vein peak systolic velocity improved from 18 to 27.7 cm/sec (p < 0.01), indicating reduced portal hypertension. No postoperative infections or variceal bleeding recurrences were noted. MIS is a safe and effective treatment option for non-bleeder NCPF with favorable long-term outcomes when performed by skilled surgeons.